The Working Group on New TB Vaccines

New vaccines are essential to ending the global tuberculosis (TB) epidemic. The Stop TB Partnership Working Group on New TB Vaccines (WGNV) helps to facilitate the development of new, more effective TB vaccines by promoting  consensus,  scientific exchange, and advocacy in support of TB research and development (R&D).

Learn More

The World Needs a New TB Vaccine

TB kills more people annually than any other infectious disease. The only licensed vaccine to prevent TB – the 100-year old BCG vaccine provides moderate, although important, protection against severe TB in infants and young children, but it does not adequately protect teens and adults, who are most at risk for developing and spreading TB.

New, more effective vaccines that protect against all forms of TB in all age groups and populations are urgently needed, and will be essential to meeting the global targets to end TB as set forth in the UN Sustainable Development Goals and the WHO End TB Strategy.

Learn More
The only licensed vaccine to prevent TB is 100 years old.

About the Working Group on New TB Vaccines

The Working Group on New TB Vaccines (WGNV) facilitates the development of new, more effective TB vaccines by:

  • Promoting collaboration and cooperation amongst multiple stakeholders
  • Providing a forum to discuss challenges to TB vaccine R&D and identify solutions
  • Helping to build consensus on key issues and questions related to TB vaccine R&D
  • Advocating for increased support and investment in TB vaccine R&D
  • Serving as the mechanism of exchange and dialogue between the Stop TB Partnership, the TB implementation and care community, the advocacy community and the TB vaccine research community
Learn More
Our purpose is to facilitate the development of a more effective TB vaccine.

Get Involved

If you would like to learn more about the WGNV and how you can be, please contact us!

Contact Us